Our Team

Davidi Vortman is the CEO of UltraSight. With over 20 years of experience as a tech entrepreneur, Davidi has founded and grown several public and private high technology companies such as Lumos Global, Comverse Technologies, and NICE Systems (NASDAQ: NICE), and has a proven track record for managing ventures with consistent revenue growth. He holds a B.S.c in Computer Science from the Hebrew University and an MBA from Kellogg-Recanati at Northwestern University.

Itay Kezurer is Co-Founder and Chief Technology Officer of UltraSight. Itay brings algorithm development in the field of computer vision and computer graphics knowledge to the team. Prior to UltraSight, Itay was an algorithmic engineer at Elbit Systems. Itay holds an MSc in Applied Mathematics and Computer Science from the Weizmann Institute of Science, and a BSc (cum laude) in Electrical Engineering from Ben-Gurion University. 

Achi Ludomirsky is Co-Founder and Chief Medical Officer at UltraSight. Achi is also a professor of pediatric cardiology and pediatrics and is the associate chair of Pediatric Outreach at NYU School of Medicine. Dr. Ludomirsky is a pioneer in fetal and pediatric heart imaging and is internationally known for his instrumental role in the development of novel imaging and therapeutic procedures for fetuses and children with congenital heart disease.

Yaron Lipman is Co-Founder and Chief Scientific Officer of UltraSight. Yaron is also an associate professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, Israel. Yaron’s research focuses on geometric modeling and processing, shape comparison and analysis, and geometric deep learning. Yaron holds a PhD from Tel Aviv University and did his postdoctoral work at Princeton University.

Xen Mendelsohn Aderka is Vice President of Marketing at UltraSight. Xen is a marketing professional with 17 years of experience in medical technology and high technology. Previously, Xen was INSIGHTEC’s VP of Marketing where she built a global marketing organization and provided the leadership, strategy and execution for global marketing programs.  Xen holds a B.A. in Journalism & Communication and Theater Arts from The Hebrew University.

Raanan Gonen is UltraSight’s Vice President of Research and Development. He is an experienced AI and machine learning architect and enterprise software professional. He has led the design of multiple AI-based products and research projects and has a proven ability to build architecture from A-Z to create a final production design. Raanan holds a BSc in Computer Science from the Tel Aviv University.

Danny Spiegelstein MD is UltraSight’s Vice President of Medical. Dr. Spiegelstein has 20+ years of medical experience in cardiovascular invasive medicine. He is an experienced clinical research investigator, managing protocols and operations in compliance with GMP and other regulatory requirements. Prior to UltraSight, Dr. Spiegelstein served as a consultant for medical start-ups in cardiology.

Noa Avisar is UltraSight’s Vice President of Clinical Affairs and has 20 years of experience in drug and device development. She led the clinical development of oncology and neurology projects at Teva Pharmaceuticals and was the project development leader for various drugs from oncology to autoimmunology. Dr. Avisar has published 13 papers in scientific journals. She holds a Ph.D. in molecular biology from Tel Aviv University with postdoctoral research in molecular immunobiology from University of California Santa Barbara.

Sarah Mowery is the Vice President of Operations at UltraSight. A board-certified clinician, with over 15 years in healthcare, Sarah brings a proven track record of building innovative and disruptive healthcare services at scale, enhancing patient and provider experience, improving accessibility to high quality healthcare, and driving organizational financial performance. Prior to UltraSight, Sarah held the role of Head of Product at Clinical Trial Services, a clinical research startup within CVS Health. 

Dr. Andrew Goldsmith is the Medical Director at UltraSight. He is the Vice Chair of Academic Affairs at Lahey Hospital and an Instructor at Harvard Medical School. Dr. Goldsmith is an avid researcher with over 50 peer-reviewed publications. He is currently an NIH principal investigator on AI POCUS research in clinical pathways in heart failure. Further, Dr. Goldsmith was a senior editor for the EMRA book on ultrasound-guided nerve blocks and a principal author in the new ACEP guidelines on ultrasound-guided nerve blocks in the ED.

Doron is chairman, director and advisor to a variety of technology companies. Previously, Doron was the CEO of Elron Electronic Industries (NASDAQ: ELRNF and TASE ) and chairman and director of Given Imaging (NASDAQ: GIVN) until its sale to Covidian.

Dr. Atherton serves as Chief Legal Officer for The Commons Project Foundation. Previously, she served as Deputy General Counsel for the Bill & Melinda Gates Foundation. Prior to the Gates Foundation, Dr. Atherton served as in-house Sr. Corporate & IP litigation at Fitzpatrick Cella Harper & Scinto. She holds a Ph.D in Cell & Molecular Biology and a J.D. from  Fordam Law.

Rick Heinick is an active board member, investor and entrepreneur in leading medical devices and pharmaceutical companies. Currently, Rick serves on the boards of TearClear, Lentechs, Theroptix and TruIris.

Yigal Erlich is the founding father of the Israeli venture capital industry and one of the most prominent figures in the Israeli high-tech arena. Yigal also served as Chief Scientist of Israel’s Ministry of Industry and Trade.

Gilad Glick is the Vice President, Venture Investments at Johnson & Johnson – Pharma Israel and MedTech Israel and Europe, where he leads a team of investors to initiate and manage equity investments to drive business innovation and deliver new and sustainable business for the Pharma and MedTech sectors.